

# Holly E Janes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3945896/publications.pdf>

Version: 2024-02-01

59  
papers

13,422  
citations

218677

26  
h-index

138484

58  
g-index

65  
all docs

65  
docs citations

65  
times ranked

21180  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 403-416.	27.0	7,910
2	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. <i>New England Journal of Medicine</i> , 2012, 366, 1275-1286.	27.0	1,699
3	HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a caseâ€“cohort analysis. <i>Lancet</i> , The, 2008, 372, 1894-1905.	13.7	670
4	Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. <i>New England Journal of Medicine</i> , 2013, 369, 2083-2092.	27.0	518
5	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. <i>New England Journal of Medicine</i> , 2021, 385, 1774-1785.	27.0	402
6	Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use. <i>Journal of Clinical Oncology</i> , 2016, 34, 2534-2540.	1.6	392
7	Adjusting for Covariates in Studies of Diagnostic, Screening, or Prognostic Markers: An Old Concept in a New Setting. <i>American Journal of Epidemiology</i> , 2008, 168, 89-97.	3.4	169
8	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120â€“MF59 in Adults. <i>New England Journal of Medicine</i> , 2021, 384, 1089-1100.	27.0	144
9	Measuring the Performance of Markers for Guiding Treatment Decisions. <i>Annals of Internal Medicine</i> , 2011, 154, 253.	3.9	120
10	Optimizing vaccine allocation for COVID-19 vaccines shows the potential role of single-dose vaccination. <i>Nature Communications</i> , 2021, 12, 3449.	12.8	101
11	FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. <i>Journal of Clinical Investigation</i> , 2014, 124, 3879-3890.	8.2	99
12	Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 606-608.	2.1	81
13	Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2013, 208, 1231-1239.	4.0	73
14	COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact. <i>Scientific Reports</i> , 2021, 11, 15531.	3.3	70
15	Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. <i>Annals of Internal Medicine</i> , 2022, 175, 1258-1265.	3.9	63
16	Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. <i>Journal of Infectious Diseases</i> , 2017, 215, 1376-1385.	4.0	59
17	Combining biomarkers to optimize patient treatment recommendations. <i>Biometrics</i> , 2014, 70, 695-707.	1.4	58
18	Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial. <i>Journal of Virology</i> , 2014, 88, 8242-8255.	3.4	55

#	ARTICLE	IF	CITATIONS
19	HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. <i>Nature Medicine</i> , 2015, 21, 1139-1141.	30.7	50
20	An Approach to Evaluating and Comparing Biomarkers for Patient Treatment Selection. <i>International Journal of Biostatistics</i> , 2014, 10, 99-121.	0.7	47
21	Assessing Treatment Selection Markers using a Potential Outcomes Framework. <i>Biometrics</i> , 2012, 68, 687-696.	1.4	46
22	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2019, 6, e737-e749.	4.7	43
23	A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic <i>Plasmodium falciparum</i> Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation. <i>Journal of Infectious Diseases</i> , 2018, 217, 693-702.	4.0	42
24	On quantifying the magnitude of confounding. <i>Biostatistics</i> , 2010, 11, 572-582.	1.5	32
25	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. <i>Journal of Infectious Diseases</i> , 2018, 217, 1280-1288.	4.0	32
26	Statistical Analysis of Air Pollution Panel Studies: An Illustration. <i>Annals of Epidemiology</i> , 2008, 18, 792-802.	1.9	29
27	The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv157.	6.3	28
28	A Framework for Evaluating Markers Used to Select Patient Treatment. <i>Medical Decision Making</i> , 2014, 34, 159-167.	2.4	26
29	Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. <i>Journal of Virology</i> , 2019, 93, .	3.4	26
30	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac124.	0.9	25
31	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , 2015, 10, e0136626.	2.5	23
32	Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 645-656.	1.1	23
33	In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Nonvaccine Prevention Modalities. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1513-1523.	1.1	19
34	Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials. <i>Lancet HIV</i> , 2019, 6, e475-e482.	4.7	19
35	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. <i>PLoS ONE</i> , 2020, 15, e0226803.	2.5	16
36	Efficient nonparametric inference on the effects of stochastic interventions under two-phase sampling, with applications to vaccine efficacy trials. <i>Biometrics</i> , 2021, 77, 1241-1253.	1.4	15

#	ARTICLE	IF	CITATIONS
37	A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. <i>Annals of Internal Medicine</i> , 2021, 174, 1118-1125.	3.9	15
38	Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. <i>Current Opinion in Virology</i> , 2016, 17, 57-65.	5.4	14
39	Designing a study to evaluate the benefit of a biomarker for selecting patient treatment. <i>Statistics in Medicine</i> , 2015, 34, 3503-3515.	1.6	11
40	Analysis of the HIV Vaccine Trials Network 702 Phase 2b HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. <i>Journal of Infectious Diseases</i> , 2022, 226, 246-257.	4.0	11
41	First things first: risk model performance metrics should reflect the clinical application. <i>Statistics in Medicine</i> , 2017, 36, 4503-4508.	1.6	10
42	Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. <i>Scientific Reports</i> , 2020, 10, 13031.	3.3	10
43	Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission. <i>Viruses</i> , 2021, 13, 1921.	3.3	10
44	Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. <i>Vaccine</i> , 2017, 35, 1184-1193.	3.8	9
45	Case-only Approach to Identifying Markers Predicting Treatment Effects on the Relative Risk Scale. <i>Biometrics</i> , 2018, 74, 753-763.	1.4	9
46	Evaluating Vaccine Efficacy Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Clinical Infectious Diseases</i> , 2022, 74, 544-552.	5.8	9
47	Power/sample size calculations for assessing correlates of risk in clinical efficacy trials. <i>Statistics in Medicine</i> , 2016, 35, 3745-3759.	1.6	8
48	Quantifying the Impact of Lifting Community Nonpharmaceutical Interventions for COVID-19 During Vaccination Rollout in the United States. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab341.	0.9	6
49	Designing HIV Vaccine Efficacy Trials in the Context of Highly Effective Non-vaccine Prevention Modalities. <i>Statistics in Biosciences</i> , 2020, 12, 468-494.	1.2	5
50	Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer. <i>Contemporary Clinical Trials</i> , 2017, 63, 30-39.	1.8	4
51	Evaluation of biomarkers for treatment selection using individual participant data from multiple clinical trials. <i>Statistics in Medicine</i> , 2018, 37, 1439-1453.	1.6	4
52	Rejoinder: Combining biomarkers to optimize patient treatment recommendations. <i>Biometrics</i> , 2014, 70, 719-720.	1.4	3
53	Designing the Next Generation of HIV Prevention Efficacy Trials: Synopsis of a 2018 Symposium. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	3
54	Use of placebos in Phase 1 preventive HIV vaccine clinical trials. <i>Vaccine</i> , 2015, 33, 749-752.	3.8	2

#	ARTICLE	IF	CITATIONS
55	The association of $\beta$ 27 expression with HIV acquisition and disease progression in people who inject drugs and men who have sex with men: Case control studies. <i>EBioMedicine</i> , 2020, 62, 103102.	6.1	2
56	RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. <i>Virus Evolution</i> , 2021, 7, veab057.	4.9	2
57	Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors. <i>PLoS ONE</i> , 2019, 14, e0222183.	2.5	1
58	Methods for comparing durability of immune responses between vaccine regimens in early-phase trials. <i>Statistical Methods in Medical Research</i> , 2020, 29, 78-93.	1.5	1
59	Discussion on "Estimating vaccine efficacy over time after a randomized study is unblinded" by Anastasios A. Tsiatis and Marie Davidian. <i>Biometrics</i> , 2022, 78, 841-843.	1.4	1